Latest California Healthline Stories
Trump Administration Is Ending Multiple HIV Vaccine Studies, Scientists and Officials Say
The cuts will shutter two major HIV vaccine research efforts, and a National Institutes of Health senior official said the agency has been instructed not to issue any more HIV vaccine research funding in the next fiscal year, with few exceptions.
Long-Covid Patients Are Frustrated That Federal Research Hasn’t Found New Treatments
The federal government has allocated $1.15 billion to long-covid research without any new treatments yet brought to market. Patients and scientists say it’s time to push harder for breakthroughs.
No Evidence Trump’s Drug Program for Terminal Patients Saved ‘Thousands’ of Lives
Though the former president has repeatedly hyped the impact of his experimental drug program, there’s no basis for his claims in government data, and medical experts say he’s exaggerating.
The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice.
Private equity-backed Headlands Research heralded its covid-19 vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.
Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
Which Companies Aren’t Exiting Russia? Big Pharma
U.S. and global drug manufacturers invested in Russia’s sizable pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion. Not everyone agrees.
Patients Divided Over Alzheimer’s Drug: Is It a ‘Risk I’m Willing to Take’ or Just a ‘Magic Pill’?
Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimer’s disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.
Diabetes Drug’s New Weight Loss Formula Fuels Cost-Benefit Debate
Health plans’ coverage of the medication, branded as Wegovy — which has a $1,300-a-month price tag — is not a sure thing.
Dying Patients With Rare Diseases Struggle to Get Experimental Therapies
When patients with common terminal illnesses such as cancer seek permission for compassionate use of therapies in the testing stage, their requests often are approved. But those with more unusual illnesses say drug companies are rarely willing to provide access.